中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 7
Jul.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(7): 1431-1436

Research advances in circadian clock genes in the development， progression， and treatment of liver cancer

DOI: 10.12449/JCH250731
  • 1.

    Spleen，Stomach and Hepatobiliary Department，The First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450008，China

  • 2.

    The First Clinical Medical College of Henan University of Chinese Medicine，Zhengzhou 450008，China

Research funding:

Scientific Research Project of National Clinical Research Base of Traditional Chinese Medicine of Henan Provincial Administration (2021JDZY003);

Construction Project of Traditional Chinese Medicine in Henan Province (STG-ZYX04-202133);

Henan Provincial Health Commission Special Project of Traditional Chinese Medicine Scientific Research (2023ZY2007)

More Information
  • Corresponding author: LIU Jiangkai， 13592553982@126.com （ORCID： 0000-0002-1529-5089）
  • Received Date: 2024-12-31
  • Accepted Date: 2025-02-20
  • Published Date: 2025-07-25
    Abstract
  • Primary liver cancer is one of the most common malignant tumors of the digestive system， and its morbidity and mortality rates are increasing year by year. Recent studies have shown that circadian clock gene disorders are closely associated with the development and progression of liver cancer， which provides a new perspective for the prevention， diagnosis， treatment， and prognosis of liver cancer. In addition， targeting circadian clock genes also shows a certain clinical application potential in the treatment of cancer. This article reviews the latest research advances in the role of circadian clock genes in the pathogenesis， prevention， treatment， and prognosis of liver cancer， in order to provide new ideas for the clinical diagnosis and treatment of liver cancer.

     

    • FullText(HTML)
  • loading
    • References(41)
  • [1]
    JIANG SA, LU H, PAN YW, et al. Characterization of the distinct immune microenvironments between hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. Cancer Lett, 2024, 588: 216799. DOI: 10.1016/j.canlet.2024.216799.
    [2]
    BARATI S, SAFFAR H, MEHRABADI S, et al. The circadian clock as a potential biomarker and therapeutic target in gastrointestinal cancers[J]. Curr Pharm Des, 2024, 30( 23): 1804- 1811. DOI: 10.2174/0113816128302762240515054444.
    [3]
    DELBÈS AS, QUIÑONES M, GOBET C, et al. Mice with humanized livers reveal the role of hepatocyte clocks in rhythmic behavior[J]. Sci Adv, 2023, 9( 20): eadf2982. DOI: 10.1126/sciadv.adf2982.
    [4]
    PADILLA J, OSMAN NM, BISSIG-CHOISAT B, et al. Circadian dysfunction induces NAFLD-related human liver cancer in a mouse model[J]. J Hepatol, 2024, 80( 2): 282- 292. DOI: 10.1016/j.jhep.2023.10.018.
    [5]
    LI SJ, SHUI K, ZHANG Y, et al. CGDB a database of circadian genes in eukaryotes[J]. Nucleic Acids Res, 2017, 45( D1): D397- D403. DOI: 10.1093/nar/gkw1028.
    [6]
    ZHANG C, MIAO JR, FAN X. The role of circadian clock-controlled mitochondrial dynamics in nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2024, 40( 8): 1670- 1676. DOI: 10.12449/JCH240826.

    张策, 苗嘉芮, 樊旭. 生物钟调控的线粒体动力学在非酒精性脂肪性肝病中的作用[J]. 临床肝胆病杂志, 2024, 40( 8): 1670- 1676. DOI: 10.12449/JCH240826.
    [7]
    CELA O, SCRIMA R, PACELLI C, et al. Autonomous oscillatory mitochondrial respiratory activity: Results of a systematic analysis show heterogeneity in different in vitro-synchronized cancer cells[J]. Int J Mol Sci, 2024, 25( 14): 7797. DOI: 10.3390/ijms25147797.
    [8]
    DANIELS LJ, KAY D, MARJOT T, et al. Circadian regulation of liver metabolism: Experimental approaches in human, rodent, and cellular models[J]. Am J Physiol Cell Physiol, 2023, 325( 5): C1158- C1177. DOI: 10.1152/ajpcell.00551.2022.
    [9]
    CHEN SY, ZHANG WX, LI X, et al. DNA polymerase beta connects tumorigenicity with the circadian clock in liver cancer through the epigenetic demethylation of Per1[J]. Cell Death Dis, 2024, 15( 1): 78. DOI: 10.1038/s41419-024-06462-7.
    [10]
    SINGH A, ANJUM B, NAZ Q, et al. Night shift-induced circadian disruption: Links to initiation of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and risk of hepatic cancer[J]. Hepatoma Res, 2024: 2394- 5079.2024.88. DOI: 10.20517/2394-5079.2024.88.
    [11]
    YE ZY, DU Y, YU WG, et al. Construction of a circadian rhythm-relevant gene signature for hepatocellular carcinoma prognosis, immunotherapy and chemosensitivity prediction[J]. Heliyon, 2024, 10( 13): e33682. DOI: 10.1016/j.heliyon.2024.e33682.
    [12]
    de MARTINO M, RATHMELL JC, GALLUZZI L, et al. Cancer cell metabolism and antitumour immunity[J]. Nat Rev Immunol, 2024, 24( 9): 654- 669. DOI: 10.1038/s41577-024-01026-4.
    [13]
    ZHAO BM, NEPOVIMOVA E, WU QH. The role of circadian rhythm regulator PERs in oxidative stress, immunity, and cancer development[J]. Cell Commun Signal, 2025, 23( 1): 30. DOI: 10.1186/s12964-025-02040-2.
    [14]
    NIAN ZG, DOU YC, SHEN YQ, et al. Interleukin-34-orchestrated tumor-associated macrophage reprogramming is required for tumor immune escape driven by p53 inactivation[J]. Immunity, 2024, 57( 10): 2344- 2361. e 7. DOI: 10.1016/j.immuni.2024.08.015.
    [15]
    KONG MY, SHI XY, GAO J, et al. BTF3 affects hepatocellular carcinoma progression by transcriptionally upregulating PDCD2L and inactivating p53 signaling[J]. Mol Med, 2024, 30( 1): 252. DOI: 10.1186/s10020-024-01044-x.
    [16]
    QU M, ZHANG GX, QU H, et al. Circadian regulator BMAL1:: CLOCK promotes cell proliferation in hepatocellular carcinoma by controlling apoptosis and cell cycle[J]. Proc Natl Acad Sci USA, 2023, 120( 2): e2214829120. DOI: 10.1073/pnas.2214829120.
    [17]
    YANG SL, YU C, JIANG JX, et al. Hepatitis B virus X protein disrupts the balance of the expression of circadian rhythm genes in hepatocellular carcinoma[J]. Oncol Lett, 2014, 8( 6): 2715- 2720. DOI: 10.3892/ol.2014.2570.
    [18]
    CHEN XL, ZHAO QS, WANG HB, et al. Period2 is associated with immune cell infiltration and is a potential diagnostic and prognostic marker for hepatocellular carcinoma[J]. Front Mol Biosci, 2023, 10: 1264553. DOI: 10.3389/fmolb.2023.1264553.
    [19]
    RAJAN PK, UDOH US, FINLEY R, et al. The biological clock of liver metabolism in metabolic dysfunction-associated steatohepatitis progression to hepatocellular carcinoma[J]. Biomedicines, 2024, 12( 9): 1961. DOI: 10.3390/biomedicines12091961.
    [20]
    SANCAR A, van GELDER RN. Clocks, cancer, and chronochemotherapy[J]. Science, 2021, 371( 6524): eabb0738. DOI: 10.1126/science.abb0738.
    [21]
    FELLOWS RC, CHUN SK, LARSON N, et al. Disruption of the intestinal clock drives dysbiosis and impaired barrier function in colorectal cancer[J]. Sci Adv, 2024, 10( 39): eado1458. DOI: 10.1126/sciadv.ado1458.
    [22]
    LIU YQ, SU ZY, TAVANA O, et al. Understanding the complexity of p53 in a new era of tumor suppression[J]. Cancer Cell, 2024, 42( 6): 946- 967. DOI: 10.1016/j.ccell.2024.04.009.
    [23]
    MILLER S, KESHERWANI M, CHAN P, et al. CRY2 isoform selectivity of a circadian clock modulator with antiglioblastoma efficacy[J]. Proc Natl Acad Sci USA, 2022, 119( 40): e2203936119. DOI: 10.1073/pnas.2203936119.
    [24]
    GU WJ, LI T, HUANG YX, et al. Metabolic profile and lipid metabolism phenotype in mice with conditional deletion of hepatic BMAL1[J]. Int J Mol Sci, 2024, 25( 11): 6070. DOI: 10.3390/ijms25116070.
    [25]
    FERRELL JM. Chronobiology of cancers in the liver and gut[J]. Cancers(Basel), 2024, 16( 17): 2925. DOI: 10.3390/cancers16172925.
    [26]
    SHENG MF, ZHANG YY, WANG YY, et al. Decoding the role of aberrant RNA alternative splicing in hepatocellular carcinoma: A comprehensive review[J]. J Cancer Res Clin Oncol, 2023, 149( 19): 17691- 17708. DOI: 10.1007/s00432-023-05474-8.
    [27]
    HUANG CJ, XIAO X, ZHOU L, et al. Chinese expert consensus statement on the clinical application of AFP/AFP-L3%/DCP using GALAD and GALAD-like algorithm in HCC[J]. J Clin Lab Anal, 2023, 37( 23-24): e24990. DOI: 10.1002/jcla.24990.
    [28]
    YAN C, CHEN XG, JIN HL, et al. Role of the criteria based on preoperative serological indexes of AFP and GGT in predicting long-term survival of patients with hepatocellular carcinoma after liver transplantation[J]. Organ Transpl, 2023, 14( 2): 248- 256. DOI: 10.3969/j.issn.1674-7445.2023.02.011.

    严成, 陈新国, 金海龙, 等. 基于术前血清学指标AFP和GGT的标准在预测肝细胞癌患者肝移植术后长期生存中的作用研究[J]. 器官移植, 2023, 14( 2): 248- 256. DOI: 10.3969/j.issn.1674-7445.2023.02.011.
    [29]
    ZHU XJ, ZHANG ZX, ZHANG JX, et al. Single-cell and bulk transcriptomic analyses reveal a stemness and circadian rhythm disturbance-related signature predicting clinical outcome and immunotherapy response in hepatocellular carcinoma[J]. Curr Gene Ther, 2025, 25( 2): 178- 193. DOI: 10.2174/0115665232298240240529131358.
    [30]
    CHI H, YANG JY, PENG GG, et al. Circadian rhythm-related genes index: A predictor for HNSCC prognosis, immunotherapy efficacy, and chemosensitivity[J]. Front Immunol, 2023, 14: 1091218. DOI: 10.3389/fimmu.2023.1091218.
    [31]
    LIU G, LUO YR, LIU JH, et al. Identification of a novel circadian rhythm-related signature for predicting prognosis and therapies in hepatocellular carcinoma based on bulk and single-cell RNA sequencing[J]. Eur J Cancer Care, 2024, 2024: 1834636. DOI: 10.1155/2024/1834636.
    [32]
    WANG C, ZENG Q, GÜL ZM, et al. Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy[J]. Cell, 2024, 187( 11): 2690- 2702. e 17. DOI: 10.1016/j.cell.2024.04.015.
    [33]
    HUANG MX, DUAN SY, ZHANG QW, et al. Deciphering the diurnal rhythm regulating mechanism of flavin-containing monooxygenase 3 in mouse liver[J]. Int J Biochem Cell Biol, 2024, 169: 106538. DOI: 10.1016/j.biocel.2024.106538.
    [34]
    OKYAR A, OZTURK CIVELEK D, AKYEL YK, et al. The role of the circadian timing system on drug metabolism and detoxification: An update[J]. Expert Opin Drug Metab Toxicol, 2024, 20( 6): 503- 517. DOI: 10.1080/17425255.2024.2356167.
    [35]
    HRUSHESKY WJ. Circadian timing of cancer chemotherapy[J]. Science, 1985, 228( 4695): 73- 75. DOI: 10.1126/science.3883493.
    [36]
    WADA K, HATTORI A, MARUYAMA Y, et al. Dietary melatonin and liver cancer incidence in Japan: From the Takayama study[J]. Cancer Sci, 2024, 115( 5): 1688- 1694. DOI: 10.1111/cas.16103.
    [37]
    NABIH HK, HAMED AR, YAHYA SMM. Anti-proliferative effect of melatonin in human hepatoma HepG2 cells occurs mainly through cell cycle arrest and inflammation inhibition[J]. Sci Rep, 2023, 13( 1): 4396. DOI: 10.1038/s41598-023-31443-9.
    [38]
    HAMED AR, YAHYA SMM, NABIH HK. Anti-drug resistance, anti-inflammation, and anti-proliferation activities mediated by melatonin in doxorubicin-resistant hepatocellular carcinoma: in vitro investigations[J]. Naunyn Schmiedebergs Arch Pharmacol, 2023, 396( 6): 1117- 1128. DOI: 10.1007/s00210-023-02385-w.
    [39]
    QIN P, LI YR, SU YJ, et al. Bifidobacterium adolescentis-derived hypaphorine alleviates acetaminophen hepatotoxicity by promoting hepatic Cry1 expression[J]. J Transl Med, 2024, 22( 1): 525. DOI: 10.1186/s12967-024-05312-6.
    [40]
    ANABTAWI N, CVAMMEN W, KEMP MG. Pharmacological inhibition of cryptochrome and REV-ERB promotes DNA repair and cell cycle arrest in cisplatin-treated human cells[J]. Sci Rep, 2021, 11( 1): 17997. DOI: 10.1038/s41598-021-97603-x.
    [41]
    GOMATOU G, KARACHALIOU A, VELOUDIOU OZ, et al. The role of REV-ERB receptors in cancer pathogenesis[J]. Int J Mol Sci, 2023, 24( 10): 8980. DOI: 10.3390/ijms24108980.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (379) PDF downloads(33) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return